Effect of Type 2 Diabetes on Biomarker Levels in Albumin Platelet-Rich Fibrin

Effect of Type 2 Diabetes on Insulin Like Growth Factor-1, Epidermal Growth Factor and Interleukin-6 Levels in Albumin Platelet-Rich Fibrin Membranes

Diabetes mellitus is a metabolic disease that can negatively affect wound healing and tissue repair. Albumin platelet-rich fibrin (Alb-PRF) is a blood-derived biomaterial used in periodontal and regenerative treatments. It contains growth factors and cytokines that may support tissue healing.

The purpose of this study is to evaluate whether type 2 diabetes affects the biological composition of Alb-PRF. For this purpose, Alb-PRF samples obtained from individuals with type 2 diabetes will be compared with samples obtained from systemically healthy individuals.

A total of 20 participants will be included in the study: 10 individuals with type 2 diabetes and 10 systemically healthy individuals. Venous blood samples will be collected from each participant, and Alb-PRF will be prepared using a standardized protocol. The prepared samples will be stored at -80°C until laboratory analysis.

The levels of interleukin-6 (IL-6), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) in Alb-PRF samples will be measured using an enzyme-linked immunosorbent assay (ELISA). These markers are related to inflammation, tissue repair, and wound healing. The results will help determine whether type 2 diabetes changes the cytokine and growth factor profile of Alb-PRF.

Inclusion Criteria:

For the type 2 diabetes group:

• Diagnosis of type 2 diabetes
• HbA1c value of at least 7%
• Age over 18 years
• Non-smoker
• No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months
• Not pregnant or lactating
• Willingness to participate in the study and signing of the informed consent form

For the systemically healthy group:

• No history of diabetes or prediabetes
• Age over 18 years
• Non-smoker
• No use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months
• Not pregnant or lactating
• Willingness to participate in the study and signing of the informed consent form

Exclusion Criteria:

• Age under 18 years
• Pregnancy or lactation
• Use of antibiotics, anti-inflammatory drugs, or systemic corticosteroids within the last 6 months
• Smoking
• Refusal to participate in the study or not signing the informed consent form